Skip to content
Crixivan(indinavir)
Crixivan (indinavir) is a small molecule pharmaceutical. Indinavir was first approved as Crixivan on 1996-03-13. It is used to treat acquired immunodeficiency syndrome in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indinavir sulfate
Tradename
Company
Number
Date
Products
CRIXIVANMerck Sharp & DohmeN-020685 DISCN1996-03-13
4 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
crixivanNew Drug Application2012-06-14
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acquired immunodeficiency syndromeEFO_0000765D000163B20
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AE: Protease inhibitors, direct acting antivirals
— J05AE02: Indinavir
HCPCS
No data
Clinical
Clinical Trials
96 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B2012311353190
Cardiovascular diseasesD002318EFO_0000319I981——1—2
Hiv-associated lipodystrophy syndromeD039682EFO_1001348———1—1
Healthy volunteers/patients————1—1
Hemophilia aD006467EFO_0007267D66———1—1
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SarcomaD012509—2———2
Kaposi sarcomaD012514C46—1———1
NeoplasmsD009369C80—1———1
TuberculosisD014376EFO_0000774A15-A1911———1
Ewing sarcomaD012512EFO_0000173—1———1
RhabdomyosarcomaD012208—1———1
Mycobacterium avium-intracellulare infectionD015270EFO_0007386—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I101————1
Acquired immunodeficiency syndromeD000163EFO_0000765B201————1
PregnancyD011247EFO_0002950Z33.11————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameINDINAVIR
INNindinavir
Description
Indinavir is a N-(2-hydroxyethyl)piperazine, a piperazinecarboxamide and a dicarboxylic acid diamide. It has a role as a HIV protease inhibitor.
Classification
Small molecule
Drug classantivirals: HIV protease inhibitors (saquinavir type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O
Identifiers
PDB—
CAS-ID150378-17-9
RxCUI114289
ChEMBL IDCHEMBL115
ChEBI ID44032
PubChem CID5362440
DrugBankDB00224
UNII ID9MG78X43ZT (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 7,594 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
5,101 adverse events reported
View more details